[go: up one dir, main page]

NO20033815L - Pharmaceutical salts - Google Patents

Pharmaceutical salts

Info

Publication number
NO20033815L
NO20033815L NO20033815A NO20033815A NO20033815L NO 20033815 L NO20033815 L NO 20033815L NO 20033815 A NO20033815 A NO 20033815A NO 20033815 A NO20033815 A NO 20033815A NO 20033815 L NO20033815 L NO 20033815L
Authority
NO
Norway
Prior art keywords
pharmaceutical salts
pharmaceutical
salts
Prior art date
Application number
NO20033815A
Other languages
Norwegian (no)
Other versions
NO20033815D0 (en
NO333986B1 (en
Inventor
Johannes Heinich Bartholomaeus
Heinrich Kugelmann
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of NO20033815D0 publication Critical patent/NO20033815D0/en
Publication of NO20033815L publication Critical patent/NO20033815L/en
Publication of NO333986B1 publication Critical patent/NO333986B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
    • C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C07C215/62—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C07C217/66—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
    • C07C217/68—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain with singly-bound oxygen atoms, six-membered aromatic rings and amino groups bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
    • C07D291/06—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)
NO20033815A 2001-02-28 2003-08-27 Pharmaceutical salts of active compounds, a drug containing them, and the use of the salts NO333986B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10109763A DE10109763A1 (en) 2001-02-28 2001-02-28 Pharmaceutical salts
PCT/EP2002/002169 WO2002067916A2 (en) 2001-02-28 2002-02-28 Pharmaceutical salts

Publications (3)

Publication Number Publication Date
NO20033815D0 NO20033815D0 (en) 2003-08-27
NO20033815L true NO20033815L (en) 2003-09-09
NO333986B1 NO333986B1 (en) 2013-11-04

Family

ID=7675871

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033815A NO333986B1 (en) 2001-02-28 2003-08-27 Pharmaceutical salts of active compounds, a drug containing them, and the use of the salts

Country Status (24)

Country Link
EP (1) EP1390023B1 (en)
JP (2) JP4737583B2 (en)
KR (1) KR20030078943A (en)
CN (2) CN100352431C (en)
AR (1) AR033423A1 (en)
AT (1) ATE395053T1 (en)
BR (1) BR0207726A (en)
CA (2) CA2725635A1 (en)
CZ (1) CZ306998B6 (en)
DE (2) DE10109763A1 (en)
ES (1) ES2307739T3 (en)
HU (1) HU229048B1 (en)
IL (2) IL157477A0 (en)
MX (1) MXPA03007712A (en)
NO (1) NO333986B1 (en)
NZ (2) NZ551440A (en)
PE (1) PE20020973A1 (en)
PL (1) PL218187B1 (en)
PT (1) PT1390023E (en)
RU (1) RU2309942C2 (en)
SI (1) SI1390023T1 (en)
SK (1) SK287574B6 (en)
WO (2) WO2002067651A2 (en)
ZA (2) ZA200410015B (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20030527A1 (en) 2001-10-24 2003-07-26 Gruenenthal Chemie DELAYED-RELEASE PHARMACEUTICAL FORMULATION CONTAINING 3- (3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL) PHENOL OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME AND ORAL TABLETS CONTAINING IT
PT1443917E (en) * 2001-11-07 2006-06-30 Synthon Bv TAMSULOSIN TABLETS
DE10163421A1 (en) * 2001-12-21 2003-07-31 Gruenenthal Gmbh Use of (+) - (1S, 2S) -3- (3-dimethylamino-1-ethyl-2-methyl-propyl) phenol as an anti-emetic
DE10224556A1 (en) * 2002-05-31 2004-01-08 Grünenthal GmbH Medicament containing 1-dimethylamino-3- (3-methoxy-phenyl) 2-methyl-pentan-3-ol in various formulations
DE10225315A1 (en) * 2002-06-06 2003-12-24 Gruenenthal Gmbh Active substance salts and esters of 1-dimethylamino-3- (3-methoxyphenyl) -2-methylpentan-3-ol and 3- (3-dimethylamino-1-ethyl-1-hydroxy-2-methylpropyl) - phenol
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
RU2005108577A (en) * 2002-09-28 2006-06-10 МакНЕЙЛ-ППС, ИНК. (US) DOSED FORMS WITH MODIFIED RELEASE
ATE465726T1 (en) 2002-11-22 2010-05-15 Gruenenthal Gmbh USE OF (1R, 2R)-3-(3-DIMENTHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL FOR THE TREATMENT OF INFLAMMATORY PAIN
DE10305984A1 (en) * 2003-02-13 2004-09-02 Helm Ag Salts of organic acids with clopidogrel and their use in the manufacture of pharmaceutical formulations
DE10329386A1 (en) * 2003-06-30 2005-01-20 Novartis Ag Aqueous solution containing opipramol salt, useful for treating depression, also includes a sugar alcohol or synthetic sweetener to improve taste and chemical stability, particularly color
DE10333835A1 (en) * 2003-07-24 2005-03-10 Gruenenthal Gmbh Sustained-release drug containing 6-dimethylaminomethyl-1- (3-methoxy-phenyl) -cyclohexane-1,3-diol
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
DE10361596A1 (en) 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
DE10356362A1 (en) * 2003-11-28 2005-06-23 Grünenthal GmbH Use of 1-phenyl-3-dimethylamino-propane compounds for the treatment of anxiety disorders
FR2865648B1 (en) * 2004-02-03 2006-06-30 Philippe Perovitch METHOD FOR DIFFUSION OF INSOLUBLE MOLECULES IN AQUEOUS MEDIUM AND COMPOSITION IMPLEMENTING SAID METHOD
DE102004032049A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
WO2006046560A1 (en) * 2004-10-29 2006-05-04 Taiho Pharmaceutical Co., Ltd. Propiverine-containing oral particulate preparation and process for producing the same
DE102005005449A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
BRPI0502736A (en) * 2005-07-05 2007-02-27 Biolab Sanus Farmaceutica Ltda oral formulations of masked residual flavor ondansetron
US20090104266A1 (en) * 2005-09-15 2009-04-23 Tobias Jung 3-(2-dimethylaminomethylcy clohexyl)phenol retard formulation
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
JP5543200B2 (en) * 2006-04-28 2014-07-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Pharmaceutical combination comprising 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and NSAID
DE102007022790A1 (en) 2007-05-11 2008-11-20 Grünenthal GmbH Axomadol for the treatment of pain in osteoarthritis
JP2009007311A (en) * 2007-06-29 2009-01-15 Lintec Corp Diphenhydramine-acesulfame adduct, process for producing the same and oral preparation containing the adduct
MX2010008138A (en) 2008-01-25 2010-08-10 Gruenenthal Gmbh Pharmaceutical dosage form.
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
US20120064219A1 (en) * 2009-06-08 2012-03-15 Firmenich Sa Extruded particles
CA2765971C (en) 2009-07-22 2017-08-22 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
EP2456425B1 (en) 2009-07-22 2015-10-21 Grünenthal GmbH Tamper-resistant dosage form for oxidation-sensitive opioids
LT3656765T (en) 2010-07-23 2021-06-10 Grünenthal GmbH Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
KR20130137627A (en) 2010-09-02 2013-12-17 그뤼넨탈 게엠베하 Tamper resistant dosage form comprising an anionic polymer
EP2611426B1 (en) 2010-09-02 2014-06-25 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
WO2012051246A1 (en) 2010-10-12 2012-04-19 Ratiopharm Gmbh Tapentadol hydrobromide and crystalline forms thereof
BR112013022495A2 (en) 2011-03-04 2016-12-06 Gruenenthal Gmbh tapentadol aqueous pharmaceutical formulation for oral administration
JP2014510067A (en) * 2011-03-04 2014-04-24 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Parenteral administration of tapentadol
PT3766489T (en) * 2011-05-03 2022-04-07 Gruenenthal Gmbh Semisolid aqueous pharmaceutical composition containing tapentadol
KR20140053159A (en) 2011-07-29 2014-05-07 그뤼넨탈 게엠베하 Tamper-resistant tablet providing immediate drug release
CN103857386A (en) 2011-07-29 2014-06-11 格吕伦塔尔有限公司 Tamper-resistant tablet providing immediate drug release
EP2819656A1 (en) 2012-02-28 2015-01-07 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
PT2838512T (en) 2012-04-18 2018-11-09 Gruenenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
AU2014273226B2 (en) 2013-05-29 2019-06-27 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
EP3019157A1 (en) 2013-07-12 2016-05-18 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
CN105934241B (en) 2013-11-26 2020-06-05 格吕伦塔尔有限公司 Preparation of powdered pharmaceutical composition by cryogenic grinding
EP2942054A1 (en) * 2014-05-09 2015-11-11 G.L. Pharma GmbH Slow-release pharmaceutical formulation
CN106572980A (en) 2014-05-12 2017-04-19 格吕伦塔尔有限公司 Tamper resistant immediate release capsule formulation comprising tapentadol
MX2016015417A (en) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticles safeguarded against ethanolic dose-dumping.
RU2588840C1 (en) * 2015-03-26 2016-07-10 Общество с ограниченной ответственностью ООО "ВАЛЕНТА-ИНТЕЛЛЕКТ" Tablet quetiapine with prolonged release and synthesis method thereof
PT3273953T (en) 2015-03-27 2019-04-01 Gruenenthal Gmbh Stable formulation for parenteral administration of tapentadol
US20160310429A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US9833408B1 (en) * 2016-07-28 2017-12-05 Allen Greenspoon Orally administrable formulation
EP3515412B1 (en) 2016-09-23 2025-04-23 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
EP3585370A1 (en) 2017-02-23 2020-01-01 Grünenthal GmbH Tapentadol as local anesthetic
DE202020104285U1 (en) 2020-07-24 2020-12-18 Grünenthal GmbH Ethyl cellulose-coated particles containing a salt of tapentadol and phosphoric acid

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362730A (en) * 1980-08-25 1982-12-07 Heinrich Mack Nachf. Chem-Pharm. Fabrik Vincamine saccharinate and a pharmaceutical composition containing it dissolved therein
DE3113132A1 (en) * 1981-04-01 1982-10-21 Heinrich Mack Nachf., 7918 Illertissen VINCAMINE CYCLAMATE, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THIS
DE3639903A1 (en) * 1986-11-22 1988-06-01 Bayer Ag SACCHARINE SALTS OF AMINOMETHYLHETEROCYCLEN
DE3639901A1 (en) * 1986-11-22 1988-06-01 Bayer Ag SACCHARINE SALTS FROM SUBSTITUTED AMINES
DE3639902A1 (en) * 1986-11-22 1988-06-01 Bayer Ag SACCHARINE SALTS FROM SUBSTITUTED HYDROXYPROPYLAMINES
US6077822A (en) * 1993-09-14 2000-06-20 Dumex-Alpharma A/S Drug salts
DE4426245A1 (en) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-phenyl-3-dimethylamino-propane compounds with pharmacological activity
DE19525137C2 (en) * 1995-07-11 2003-02-27 Gruenenthal Gmbh 6-Dimethylaminomethyl-1-phenyl-cyclohexane compounds as intermediates for the preparation of pharmaceutical agents
DE19601744C2 (en) * 1996-01-19 1998-04-16 Gruenenthal Gmbh Process for the preparation of the enantiomers of O-demethyltramadol
SI0932617T1 (en) * 1996-10-18 2002-06-30 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
WO2000012067A1 (en) * 1998-08-27 2000-03-09 Bristol-Myers Squibb Company Novel pharmaceutical salt form
ATE279186T1 (en) * 1999-08-31 2004-10-15 Gruenenthal Gmbh SUSTAINED-RELEASE PHARMACEUTICAL FORM CONTAINING TRAMADOL ACCHARINATE
DE19947747A1 (en) * 1999-10-05 2001-04-12 Gruenenthal Gmbh Treatment of urinary incontinence using (+)-tramadol, O-demethyl-tramadol or O-demethyl-N-mono-desmethyl-tramadol, having strong effect on bladder function without side-effects or analgesic action
DE10013259A1 (en) * 2000-03-17 2001-09-20 Nutrinova Gmbh New stable complexes of acesulfame with trace elements e.g. zinc or copper, useful as taste-masked form of trace elements for use in foods, feedstuffs, pharmaceuticals or cosmetics
DE10013712A1 (en) * 2000-03-20 2001-09-27 Nutrinova Gmbh Nicotine salts with improved taste, process for their preparation and their use
DE10059412A1 (en) * 2000-11-30 2002-06-13 Gruenenthal Gmbh Use of 1-phenyl-3-dimethylamino-propane compounds for the treatment of urinary incontinence
DE10130298A1 (en) * 2001-06-22 2003-01-23 Nutrinova Gmbh Antimicrobial acesulfame complexes, process for their preparation and their use

Also Published As

Publication number Publication date
AR033423A1 (en) 2003-12-17
CN1561203A (en) 2005-01-05
CN100352431C (en) 2007-12-05
NO20033815D0 (en) 2003-08-27
DE50212273D1 (en) 2008-06-26
HK1064035A1 (en) 2005-01-21
JP2004527491A (en) 2004-09-09
NO333986B1 (en) 2013-11-04
KR20030078943A (en) 2003-10-08
ES2307739T3 (en) 2008-12-01
CZ306998B6 (en) 2017-11-08
HUP0303325A3 (en) 2008-03-28
PE20020973A1 (en) 2002-10-26
CZ20032315A3 (en) 2003-11-12
DE10109763A1 (en) 2002-09-05
SK10612003A3 (en) 2004-01-08
PL218187B1 (en) 2014-10-31
CA2439269A1 (en) 2002-09-06
BR0207726A (en) 2004-07-27
WO2002067916A2 (en) 2002-09-06
RU2309942C2 (en) 2007-11-10
EP1390023B1 (en) 2008-05-14
CA2439269C (en) 2011-11-01
SK287574B6 (en) 2011-03-04
RU2003127396A (en) 2005-03-20
ZA200306529B (en) 2005-03-30
PL364223A1 (en) 2004-12-13
CA2725635A1 (en) 2002-09-06
HU229048B1 (en) 2013-07-29
JP2011079843A (en) 2011-04-21
ZA200410015B (en) 2005-09-28
WO2002067916A3 (en) 2003-12-18
ATE395053T1 (en) 2008-05-15
CN101125137A (en) 2008-02-20
WO2002067651A2 (en) 2002-09-06
NZ551440A (en) 2007-08-31
IL157477A0 (en) 2004-03-28
SI1390023T1 (en) 2008-10-31
JP4737583B2 (en) 2011-08-03
IL157477A (en) 2009-12-24
EP1390023A2 (en) 2004-02-25
PT1390023E (en) 2008-07-30
HUP0303325A2 (en) 2004-01-28
MXPA03007712A (en) 2004-03-16
NZ528302A (en) 2007-02-23

Similar Documents

Publication Publication Date Title
NO20033815L (en) Pharmaceutical salts
EE200300416A (en) Pharmaceutical form
NO20033384L (en) Pharmaceutical Formulation
ATE319451T1 (en) TETRAHYDROCINOLINE DERIVATIVES
NO20035634D0 (en) Diamine derivatives
DK3210637T3 (en) Infusion set
DK1383560T4 (en) Infusion set
NO20033556L (en) Pharmaceutical Formulations
ATE312827T1 (en) 3-SUBSTITUTED-4-PYRIMIDONE DERIVATIVES
DE60212066D1 (en) SUPPLY SYRINGE
NO20035627D0 (en) Pharmaceutical formulation
NO20035315D0 (en) Pharmaceutical combinations
DE50209245D1 (en) NEUROPROTEKTIVES MEDICAMENT
DK1399355T3 (en) ControLLer
NO20025805D0 (en) Pharmaceutical preparation
DE60223031D1 (en) ARYLPIPERAZINE-BOUND TETRAHYDROINDOLON DERIVATIVES
ITMI20011240A0 (en) DRUGS FOR VASCULOPATHIES
ITMI20011744A0 (en) DRUGS FOR VASCULOPATHIES
DE60202381D1 (en) PAROXETINE-N-FORMYL DERIVATIVES
ATA8202001A (en) drug applicator
FI20012242A0 (en) New pharmaceutical compounds
ATE405973T1 (en) CONNECTION
NO20041236L (en) Pharmaceutical Formulation
DE60201822D1 (en) sterilization
SE0102823D0 (en) New drug

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees